HHS-OIG – Page 7 – Policy & Medicine

Sun Pharma Subsidiary Agrees to Pay $20.75 Million to Resolve False Claims Act Allegations

HHS OIG Report Finds Opioid Use Decreasing on Medicare Part D

Taro Enters into Deferred Prosecution Agreement Over Generic Drug Scheme

HHS OIG to Audit CARES Act Provider Relief Funds

Novartis Settlements and Corporate Integrity Agreement 2020 Version 3.0

HHS OIG Publishes Semiannual Report to Congress Detailing Efforts to Combat Fraud and Abuse

HHS OIG Provides Video Briefing Regarding COVID-19 Response

NY State Overbilled Medicaid Almost $40 Million for Opioid Treatment Programs

HHS OIG Issues Advisory Opinion on Provider-Paid Travel for Rare Disease Patients

Patient Services, Inc. Settlement and Corporate Integrity Agreement